Daniel Matlis

Daniel has three decades of industry experience spanning the Life-Science value network. He is an active contributor to FDA’s Case for Quality Initiative (since 2014), is a member of FDA’s Advisory Council on Modeling, Simulation and in-Silico Clinical Trial, and has co-chaired the Product Quality Outcomes Analytics initiative with Agency officials.